Investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issue
Hoersholm, Denmark, March 29, 2017 – As previously announced Oncology Venture Sweden AB (“Oncology Venture”) has already agreed on subscription commitments of approximately 18.9 MSEK, representing approximately 35.7 % of the issue volume in the ongoing rights issue. The company today announces that investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issue. Among that, Sass & Larsen ApS agreed to subscribe for an additional approximately 2.3 MSEK and Viggo Harboe 2006 Holding ApS about another 1 MSEK in addition to the subscription